BACKGROUND
==========

Organised screening programmes for cervical cancer using Pap smears have been shown to be effective in decreasing mortality and incidence from the disease ([Fidler *et al*, 1968](#bib11){ref-type="other"}; [Hakama and Räsänen-Virtanen, 1976](#bib14){ref-type="other"}; [Hakama, 1982](#bib12){ref-type="other"}; [Day, 1986](#bib10){ref-type="other"}; [Läärä *et al*, 1987](#bib17){ref-type="other"}; [Lynge, 2000](#bib20){ref-type="other"}). Opportunistic or nonorganised screening also decrease cervical cancer rates, although not to the extent of organised programmes ([Magnus and Langmark, 1986](#bib22){ref-type="other"}; [Lynge *et al*, 1989](#bib21){ref-type="other"}; [Nieminen *et al*, 1999](#bib24){ref-type="other"}). One problem with nonorganised screening is that it may not adequately cover the population targeted, sometimes missing those at highest risk ([Coleman *et al*, 1993a](#bib8){ref-type="other"}).

If clinical and diagnostic quality are not monitored and evaluated systematically, as in nonorganised screening, there are also concerns that adverse effects may become more common ([Council of the EU, 2003](#bib34){ref-type="other"}). The goal of an organised programme, along with achieving reasonable effectiveness, is that potential adverse effects are minimised while screening-related improvements in the quality of life maximised. Overuse of services can be prevented and a complete evaluation can be implemented only within the framework of an organised programme.

The European Union (EU) currently recommends that cancer screening should only be offered on a population basis in organised screening programmes, with quality assurance at all levels ([Council of the EU, 2003](#bib34){ref-type="other"}). There are also some more detailed recommendations describing the implementation, registration, monitoring, training, compliance, and introduction of novel tests of organised cancer screening programmes ([Advisory Committee on Cancer Prevention, 2000](#bib1){ref-type="other"}; [Sankila *et al*, 2000](#bib30){ref-type="other"}; [Council of the EU, 2003](#bib34){ref-type="other"};). Managerial guidelines have also been published by the WHO, and there are guidelines in several areas or individual countries describing how to organise a programme.

In Europe, there are wide variations in the organisation of cervical cancer screening activities ([Linos *et al*, ed., 2000](#bib19){ref-type="other"}). The present study aims to describe the main policy and organisational elements in cervical cancer screening programmes in many European countries, and compare them with the EU and other recommendations.

MATERIALS AND METHODS
=====================

The study is based on a questionnaire survey, collected in late 2003 from 20 European countries within the framework of a collaborative research project of the European Cervical Cancer Screening Network (ECCSN), funded by the Europe Against Cancer programme, and the International Agency for Research on Cancer (IARC), Lyon. The questionnaire survey was conducted in August--December 2003. The present report summarises the current and historical screening situation in Europe. However, as these data were also collected within the framework of interpreting long-term cervical cancer trends at a population level, only European countries or regions for which cervical cancer mortality and/or incidence data met eligibility criteria for the assessment of cervical cancer trends were included.

More specifically, countries or regions were selected according to the following criteria: Countries with mortality data available for more than 10 years (not necessarily consecutively) in the WHO mortality database up to 2000, and where 'Not Otherwise Specified' uterine cancer deaths accounted for less than 25% of all uterine cancer deaths (these NOS uterine cancer deaths can be redistributed based on the age-specific proportion of registered cervix and corpus cancer deaths ([Arbyn and Geys 2002](#bib4){ref-type="other"}; [Bray *et al*, 2002](#bib7){ref-type="other"})).Countries without mortality data meeting the above quality criteria, but for which cervical cancer incidence data of sufficient quality was available, either nationwide, or within a specific region. Criteria for data quality consisted of cancer registry-based incidence data published in at least three consecutive volumes of 'Cancer incidence in five continents' from IARC ([Parkin *et al*, 1992](#bib25){ref-type="other"}, [1997](#bib26){ref-type="other"}, [2002](#bib27){ref-type="other"}).

Countries meeting criteria for mortality data were: the Czech Republic, Denmark, Estonia, Finland, Hungary, Iceland, Lithuania, Luxembourg, the Netherlands, Norway, Switzerland, and the UK. Countries and regions meeting criteria for incidence data were: France (regional data only, from eight regions: Bas-Rhin, Calvados, Doubs, Herault, Isére, Limousin, Somme, Tarn); Germany (Saarland only); Italy (from four regions: Florence, Parma, Ragusa, Varese, and two cities: Genova, Torino); Poland (Cracow only); Slovakia, Slovenia, Spain (from four regions: Catalonia, Granada, Murcia, Navarra), and Sweden. For countries with only regional incidence data, region-specific information on cervical cancer screening was requested.

Emphasis was placed on collecting both current and historical information on the following: *Screening policy:* Year of programme initiation; target age range of screening; screening interval for women with normal results; financial cost of the smear to the women;*Organisational issues:* Whether all women in the target population are invited, or only those without a recent smear; the manner in which women are invited (personally or otherwise); the data source from which invitations are drawn; whether invitations and visits are centrally registered on an individual basis; if there had been, historically, important changes in the screening organisation;*Process and performance measures:* Invitational and geographical coverage of the programme or policy; screening attendance; proportion of women tested at least once within the recommended interval; availability of data on detection rates of histologically confirmed cancerous or precancerous findings, by severity of lesions.

We also enquired as to how estimates on screening parameters were collected and calculated in order to assess the reliability of the reported information, and we also searched for all published information on the programmes.

Different organisational definitions affect the applicability of the concept, while invitational coverage can apply only among invitational programmes. Another measure of coverage, the proportion of the target population subject to formal programme or policy ([van Ballegooijen *et al*, 2000](#bib35){ref-type="other"}), was included in the tables. In addition, proportion of women tested at least once within the recommended interval was used. The latter attendance rate is a combined measure of invitational coverage and related attendance, plus noninvitational smear-taking activity.

In addition to smears taken within programmes, spontaneous smears taken outside the programme were reported by several centres. Lack of information prevented their inclusion in detail in all performance measures. For those programmes, which registered smears, proportions of women tested at least once during the recommended interval could be calculated from the register-based source. For those programmes that registered only the invitational programme, corresponding estimates were based usually on questionnaire surveys where the reliability of the information may be limited due to reporting and selection biases. Owing to the lack of information, calculations could not be carried out for some other relevant time windows, such as smears during the last 10 year period.

The 2003 survey was sent to 35 centres in 20 countries and was completed by 28 centres from 20 countries. In the returned questionnaires from Estonia, Cracow (Poland), and Somme (France), it was reported that no 'organised programme or otherwise defined screening policy for cervical cancer' existed and there were no responses to further questions on screening activities. Therefore, these countries/regions were not included in the detailed tables. All the questionnaire information was managed in a database at IARC.

RESULTS
=======

Details of screening policy are included in [Table 1](#tbl1){ref-type="table"} Table 1Screening policy in the 18 European countries**Country/regionOnset of screening programme or policyAge range targeted (since year)Recommended screening intervalCharge of smear for the womenRecommended number of lifetime smears**Czech Republic1966Not specified (1966)1 yearFreeNot specifiedDenmark196723--59 (1986)3 years (some counties 5 years in \>45 or 50)Free13Finland196330--60 (1993)5 yearsFree7Hungary2003, pilot 199725--65 (1997)3 years, after one negative smearFree15Iceland196420--69 (1988)2 yearsPartial contribution (31 USD)25Lithuania200130--60 (2001)5 yearsFree or partial contribution (5 euro)7Luxembourg196215+ (1990)1 yearFree∼70Netherlands198030--60 (1996)5 yearsFree7Norway1995, pilot 1992 (programme in one county in 1959--1977)25--69 (1992)3 yearsPartial contribution15Slovakia--- (intention)25--64 (---)3 yearsFree14Slovenia2003 (1955 opportunistic)20--64 (2002)3 yearsFree15Sweden1967--1973 in different counties, Gothenburg 197723--60 (1999)3 years in ages 23--50 years; 5 years in ages 51--60 yearsComplete contribution in most counties; free or partial in some counties12SwitzerlandNo data18--69 (---)3 yearsPartial contribution18UK198820--64 (1988, under review)3--5 years (currently 3 years in ages 25--49 years and 5 years in ages 50--64 years)Free10--17 (12)France      Bas-Rhin199425--65 (1990)3 yearsPartial contribution14 Doubs199320--65 (1993)3 years (after two normal exams with 1 year interval)Reimbursement17 Isére199050--69 (1990)3 yearsFree7Germany      Saarland197120--85+ (1982)1 yearFree∼65Italy      Florence198225--64 (1995)3 yearsFree14 Genova199225--64 (1992)3 yearsFree14 Parma199825--64 (1998)3 yearsFree14 RagusaNo data25--64 (1996)3 yearsFree14 Torino199225--64 (1992)3 yearsFree14 VareseNo data25--64 (1996)3 yearsFree14Spain      CataloniaNo data20--64 (1993)3--5 years: initially two smears 1 year apart. Then, 3 years in ages 20--34 years and 5 years in ages 35--64 yearsFree or partial contribution12, irrespective of whether organised, spontaneous, or nonspecific screening programmes were in place. Six countries (the Czech Republic, Denmark, Finland, Iceland, Luxembourg, Sweden) reported having started screening in the 1960s, whereas 10 other countries or regions (Hungary, Lithuania, Norway, Slovenia, Bas-Rhin, Doubs, Isere, Genova, Parma, Torino) had started at least a pilot by 2003. There were large differences in target age range and interval. Recommended lifetime number of smears varied from seven (Finland, Lithuania, Netherlands, Isere) to more than 50 (Luxembourg, Germany).

The cost covered by the screened women varied widely. In most of the regions (17 out of 25; 68%), screening was free of charge for the women but in several programmes payment practices varied even within the programme, depending on the area or mode of screening activity.

Six countries/regions had invitational programmes (Finland, Hungary, the Netherlands, Isére, Parma, Torino), whereas nine countries/regions (Denmark, Iceland, Norway, Slovenia, Swdeden, United Kingdom, Bas-Rhin, Doubs, Florence) invited only those women who had not had a smear (usually opportunistic) recently or within the recommended interval ([Table 2](#tbl2){ref-type="table"} Table 2Organisation characteristics in screening for cervical cancer in the 18 European countries**Country/regionAre women in the target population invited personally to participate?How women are invited/smears offeredSource of personal invitationsIs screening registered on an individual basis?Information available on screen-detected histological findings?Remarks**Czech RepublicNoOpportunity---NoNo DenmarkYes, only women without a recent smearLetter or opportunityPopulation, pathology and health insurance registriesNo national registration. Varies between counties, most have all smears and histology in the county pathology registerNoOrganised screening was introduced gradually county-wise. Information on screening and histological findings can be collected as a research activityFinlandYesLetterPopulation registryYes, centrally, invitational programmeYesOrganised screening introduced gradually during 1963--1970; invitational coverage almost complete since 1971HungaryYesLetterSocial security register and health insurance fundsYes, centrally, invitational programmeNo IcelandYes, only women without a recent smearLetter or opportunityPopulation registryYes, centrally, allYesComputerised call-recall system from 1964. About 70% of smears in 2000 were from the invitational programmeLithuaniaNo (yes in some regions)Opportunity, announcements, mass mediaHealth service registersYes, centrally (in 10 out of 60 regions), invitational programmeYes LuxembourgNoOpportunity---Yes, most of them at the national health laboratoryYesReorganisations in 1980 and 1990NetherlandsYesLetterPopulation registryYes, both centrally and regionally, allYes NorwayYes, only women without a recent smearLetter or opportunityPopulation registryYes, centrally, allYes SlovakiaNo (yes in some districts)Letter or opportunityHealth service registersNoNo SloveniaYes, only women without a recent smearLetter or opportunityPopulation and health service registersYes, centrally, allYes (under construction) SwedenYes, only women without a recent smearLetter or opportunityPopulation registryYes, regionally, all. A central register under constructionYes (under construction) SwitzerlandNoOpportunity------No UKYes, only women without a recent smearLetter or opportunityHealth services registerYes, centrally and regionally, allYesComputerised call-recall in 1988. Target incentive payments to GPs since 1990. National coordination and quality assurance introduced in 1995France       Bas-RhinYes, only women without a recent smearLetter or opportunityHealth service registerYes, regionally, allYes  DoubsYes, only women without a recent smearLetter and/or campaignSocial security registerYes, regionally, allNo data  IséreYesLetterSocial security registerYes, regionally, invitational programmeNo dataPap smear screening in connection with breast cancer screeningGermany       SaarlandNoSmears offered through health insurance scheme---NoNo Italy       FlorenceYes, only women without a recent smearLetter or opportunityPopulation registryYes, regionally, allYes  GenovaNoOpportunity---NoNo  ParmaYesLetterPopulation and health service registerYes, regionally, invitational programmeYes  RagusaNoOpportunity---NoNo  TorinoYesLetterPopulation registryYes, regionally, invitational programmeYes  VareseNoOpportunity---NoNoScreening campaigns in the past within part of the areaSpain       CataloniaNoOpportunity---NoYes ). The other regions did not invite women, but screening was offered mainly at the occasion of a visit to a general practitioner or gynaecologist.

All of the six fully invitational programmes also had a centralised national or regional screening registration database arranged on an individual basis. Five of these registers included only the invitational programme and one (the Netherlands) included any smears. From among the programmes with partial invitations, two programmes (Denmark, Sweden) did not have a centralised national registration unit. The rest of the national programmes with a partial invitational activity reported a central national registration system, and these registers aimed to include all smears, whether taken after invitation or otherwise. Of the 10 countries/regions with opportunistic screening policies, eight were without screening registration and two had partial registration.

Smear test coverage above 80% of the target population during the recommended screening interval was reported in three national programmes (Finland, Sweden, UK); and the smear coverage was 75--80% in three countries (Denmark, Iceland, the Netherlands).

A total of 11 programmes reported collection of information on histologically confirmed lesions ([Table 2](#tbl2){ref-type="table"}). Six of these programmes reported detection rates by grade of the histological finding (Finland, Iceland, Norway, Bas-Rhin, Florence, Torino) and one country (the Netherlands) did not separate invasive cancers from the CIN3 ([Table 3](#tbl3){ref-type="table"} Table 3Process and performance values in screening for cervical cancer in the 18 European countries   **Detection rate (%)Country/regionPopulation subject to formal programme (in ages 25--64 years unless specified)Women screened within recommended interval (%), any smears included (in ages 25--64 years in 2000 unless specified)Invasive (ICC)CIN3CIN1-2**Czech republicNo dataNo dataNo dataNo dataNo dataDenmark90% (23--59)75% (23--59, 1997)No dataNo dataNo dataFinland100% (30--60)93% (35--64, 1997)0.010.130.21HungaryNo data30%No dataNo dataNo dataIceland100%76% within a 3-year interval (25--69)0.0150.470.27LithuaniaNo dataNo dataNo dataNo dataNo dataLuxembourgNo data39% (1 year, 1999)^a^No dataNo dataNo dataNetherlands100% (30--60)^b^77% (30--60, 1997)^b^No data0.35 (incl. CIN3+)0.13Norway100%70%0.04^c^0.50^c^0.79^c^SlovakiaNo dataNo dataNo dataNo dataNo dataSlovenia31% in 200070%No dataNo dataNo dataSweden100%^b^83 (23--59; 1997)^b^No dataNo dataNo dataSwitzerlandNo dataNo data^d^No dataNo dataNo dataUK100%83%No dataNo dataNo dataFrance      Bas-RhinNo data69%^e^0.050.350.73 Doubs88%\>50%No dataNo dataNo data IséreNo data69% (50--69, 1996)No dataNo dataNo dataGermany      Saarland90%^b^50% per year (20+; 1996); 80% within 3 years^b^No dataNo dataNo dataItaly      Florence100%73%0.0080.130.12 GenovaNo data53%^f^No dataNo dataNo data Parma100%66%No dataNo dataNo data RagusaNo data53%^f^No dataNo dataNo data Torino100%\>74%0.0110.090.14 VareseNo data53%^6^No dataNo dataNo dataSpain      CataloniaNo dataNo data0.040.060.8[^1][^2][^3][^4][^5][^6]). Histological information was also reported from Catalonia, a region with opportunistic activity only. No published routine monitoring information was available for other programmes. There was a wide variability in the rates between the seven programmes from 0.008 to 0.04% for invasive cancer, from 0.06 to 0.50% for CIN3, and from 0.12 to 0.8% for CIN1-2. CIN3 : invasive cancer detection ratios ranged from 1.5 to 12.

DISCUSSION
==========

The European Union has currently recommended that cancer screening should only be offered on a population basis in organised screening programmes, with quality assurance at all levels ([Council of the EU, 2003](#bib34){ref-type="other"}). There are also more detailed recommendations that are valuable in relation to organisational aspects ([Advisory Committee on Cancer Prevention, 2000](#bib1){ref-type="other"}; [Council of the EU, 2003](#bib34){ref-type="other"}). The present questionnaire-based survey indicates that these recommendations are met in only a few European countries.

The most serious inadequacies relate, according to our survey, to: (1) low or inadequate coverage of the screening test within the populations targeted; (2) shortcomings in routine registration, evaluation, and monitoring; and (3) excessive numbers of lifetime smears recommended. There also exist relatively short screening intervals that are not justified as present knowledge of the natural history of cervical cancer, particularly on the duration of precancerous stage. Such aspects as payment strategies, possibly affecting attendance, varied greatly, indicating a potential for inequality.

Incidence and mortality rates from cervical cancer can be decreased by at least 80% by means of screening. This has been shown from follow-up studies of women screened negative ([Day, 1986](#bib10){ref-type="other"}), cohort follow-up studies among screened women ([Fidler *et al*, 1968](#bib11){ref-type="other"}; [Hakama and Räsänen-Virtanen, 1976](#bib14){ref-type="other"}; [Lynge, 2000](#bib20){ref-type="other"}), and population-based follow-up studies ([Hakama 1982](#bib12){ref-type="other"}; [Day, 1986](#bib10){ref-type="other"}; [Läärä *et al*, 1987](#bib17){ref-type="other"}). Declines of this order have been observed in Canada (British Columbia) ([Anderson *et al*, 1988](#bib2){ref-type="other"}) and in Finland and Iceland ([Läärä *et al*, 1987](#bib17){ref-type="other"}; [Sigurdsson, 1999](#bib33){ref-type="other"}; [Anttila and Läärä, 2000](#bib3){ref-type="other"}). In the other Nordic countries, decreases of between 40 and 60% have been reported ([Sigurdsson, 1999](#bib33){ref-type="other"}), while the reduction tends to be of a somewhat lower order of magnitude in other regions and countries ([Coleman *et al*, 1993b](#bib9){ref-type="other"}; [Beral *et al*, 1994](#bib6){ref-type="other"}). Information is variable and often very limited, however, concerning the screening activities or incidence or death rates before the assumed time that screening started. These data as well as the current estimates of cervical cancer in Europe ([Bray *et al*, 2002](#bib7){ref-type="other"}) suggest that meaningful additional decreases in the cervical cancer rates are still possible. It is important therefore to utilise the available data continually to monitor cervical incidence and mortality rates in these populations.

The current data were obtained from areas covered by long-standing cancer registries. Therefore, they may not be representative of the entire European situation. Frequently there is a link between pilot programmes for cervical cancer screening and cancer registration, given the utility of the latter using planning and screening evaluation. For example in France, all three existing regional programmes were in areas with a cancer registry considered to satisfy minimal quality assurance prerequisites. The study may thus overestimate the presence of organised programmes.

The reported CIN3 detection rates varied eight-fold. This can be expected to result in *t* differences in related treatment rates. These differences are apparently not explained by differential screening intervals or age ranges. Variation in the background risk could provide a partial explanation, but the variations in cancer to CIN3 detection ratios suggest that differential diagnostic and registration criteria may play a major role.

The disadvantages of cancer screening include: anxiety among those screened positive or treated for a lesion, complications, potential of unnecessary medical interventions (e.g. among false-positives), overtreatment of questionable or nonprogressive abnormalities, costs incurred, longer morbidity for cases whose prognosis is unaltered, and also false reassurance that can result in delayed presentation or investigation of symptoms for persons with false-negative test results ([Hakama, 1991](#bib13){ref-type="other"}; [Bennetts *et al*, 1995](#bib5){ref-type="other"}; [Lauver *et al*, 1999](#bib18){ref-type="other"}; [Peters *et al*, 1999](#bib28){ref-type="other"}; [Rogstad, 2002](#bib29){ref-type="other"}; [Idestrom *et al*, 2003](#bib15){ref-type="other"}). Quality-of-life and potential adverse aspects should be included in the evaluation of the screening programmes. These also represent important aspects to be considered for any potential new screening techniques to be implemented in programmes.

Several Eastern European countries, which had established cancer registries, were included in this questionnaire study, but most had not implemented an organised screening programme. It should be noted that mortality rates are uniformly increasing in several countries in this region ([Beral *et al*, 1994](#bib6){ref-type="other"}; [IARC, 2002](#bib16){ref-type="other"}). Whenever possible, cancer registries should be involved in the planning and monitoring of screening programmes. Availability of local resources needs to be carefully taken into account. Given limited screening resources, the programme should be started in a few age groups, with high coverage being prioritised.

In general, there are large variations in European cervical cancer screening policies and in the organisation of programmes. Limited details are available on process and performance measures, and their correlation with effectiveness is not known. In particular, registration, monitoring, and evaluation are deficient. The EU Council recommendation states that 'subsequent monitoring and data collection on the extent to which the proposed measures are working effectively need to be arranged for the next 3-year period'. Decision-makers and health-care service providers need to consider stronger measures and incentives than the current recommendations in order to deliver successful cervical cancer control in Europe.
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